- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00779935
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
May 10, 2017 updated by: Merck Sharp & Dohme LLC
Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study
This is a Phase 4, multi-center, open-label, one-arm, pilot study in patients with active ankylosing spondylitis refractory to conventional treatment.
Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
The number of patients showing ASAS-20 clinical response at Week 14 will be evaluated.
Study Overview
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of ankylosing spondylitis proven by appropriate diagnostic methods (according to New York criteria).
- Refractory disease defined by failure of at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) during a 3-month period and failure of sulfasalazine in subjects with associated peripheral arthritis.
Active disease defined by:
- sustained BASDAI of at least 40 on a 0-100 scale and
- expert opinion based on clinical features.
- Age between 18 and 70 years.
- Subjects using NSAIDs and/or sulfasalazine must have been on a stable dose for at least 4 weeks prior to study initiation, and may continue medication during the treatment period, but the dose must not be increased above the baseline.
- Subjects must be capable to demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Men and women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (eg, hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (eg, hysterectomy or tubal ligation).
- Subjects must understand and be able to adhere to the dosing and visit schedules.
Exclusion Criteria:
- Subject with moderate or severe heart failure (NYHA class III/IV).
- Remicade must not be given to subjects with a history of hypersensitivity to infliximab, to other murine proteins, or to any of the excipients.
- Subjects with pre-existing or recent onset of central nervous system demyelinating disorders.
- Age <18 or >70 years.
- Pregnant women, nursing mothers.
- Subjects who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care.
- Subjects who have any current systemic inflammatory condition with signs and symptoms that might confound the evaluations of benefit from infliximab therapy.
- Prior administration of infliximab or any other therapeutic agent targeted at reducing TNF (eg, Etanercept, pentoxifylline, thalidomide or anti-CD4+ antibody).
- Current treatment with systemic corticosteroid.
- Treatment with any investigational drug within the previous 3 months.
- History of known allergies to murine proteins.
- Subjects having active or inactive tuberculosis (TB). All subjects must be evaluated for both active and inactive ('latent') TB. This evaluation should include a detailed medical history with personal history of TB or possible previous contact with TB and previous and/or current immunosuppressive therapy. Appropriate screening tests (ie, tuberculin skin test and chest x-ray) should be performed in all subjects.
- Serious infection, such as sepsis, abscesses, hepatitis, pneumonia, pyelonephritis in the previous 3 months. Less serious infections in the previous 3 months, such as acute respiratory tract infection (colds) or uncomplicated urinary tract infection need not be considered exclusions at the discretion of the treating physician.
- History of opportunistic infections such as herpes zoster within 2 months of study initiation. Evidence of active CMV, active pneumocystis carinii, drug resistant atypical mycobacterium, etc.
- Documented HIV infection.
- Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological, or cerebral disease.
- Any currently known malignancy or pre-malignant lesions or any history of malignancy within the past 5 years (except non-melanoma skin cancer and surgically cured cervical cancer).
- Subjects with alcoholism, alcoholic liver disease, or other chronic liver disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remicade
Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
|
Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate whether baseline serum VEGF concentration predicts ASAS-20 clinical response to infliximab at Week 14.
Time Frame: Week 14
|
Week 14
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To detect clinical response rates at Weeks 2, 6, 14, 30, 54, and at Follow-up Visit 2, which is 6 months after completion of study treatment.
Time Frame: Weeks 2, 6, 14, 30, 54 and 6 months afterwards
|
Weeks 2, 6, 14, 30, 54 and 6 months afterwards
|
To measure the duration of response
Time Frame: Weeks 2, 6, 14, 30, 54 and 6 months afterwards
|
Weeks 2, 6, 14, 30, 54 and 6 months afterwards
|
To detect the percent of patients reaching partial response
Time Frame: Weeks 2, 6, 14, 30, 54 and 6 months afterwards
|
Weeks 2, 6, 14, 30, 54 and 6 months afterwards
|
To measure the duration of partial response
Time Frame: Weeks 2, 6, 14, 30, 54 and 6 months afterwards
|
Weeks 2, 6, 14, 30, 54 and 6 months afterwards
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2004
Primary Completion (Actual)
October 1, 2005
Study Completion (Actual)
February 1, 2007
Study Registration Dates
First Submitted
October 23, 2008
First Submitted That Met QC Criteria
October 23, 2008
First Posted (Estimate)
October 24, 2008
Study Record Updates
Last Update Posted (Actual)
May 11, 2017
Last Update Submitted That Met QC Criteria
May 10, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P04041
Plan for Individual participant data (IPD)
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spondylitis, Ankylosing
-
Shanghai Junshi Bioscience Co., Ltd.Sponsor GmbHRecruitingActive Ankylosing SpondylitisChina
-
AbbVieBoehringer IngelheimCompletedAnkylosing Spondylitis (AS)
-
Sun Yat-sen UniversityUnknownEarly Ankylosing Spondylitis
-
AbbVieCompletedAnkylosing Spondylitis (AS)United States, Australia, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, United Kingdom
-
Tongji HospitalWuhan Central Hospital; Wuhan Hospital of Traditional Chinese MedicineRecruitingAnkylosing Spondylitis (AS)China
-
Chinese University of Hong KongCompletedAnkylosing Spondylitis(AS)China
-
AbbVieCompletedAnkylosing Spondylitis (AS)Taiwan
-
Tianjin Hemay Pharmaceutical Co., LtdCompletedActive Ankylosing SpondylitisChina
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingActive Ankylosing SpondylitisChina
-
Assiut UniversityUnknownActive Sacroiliitis in Ankylosing Spondylitis
Clinical Trials on Remicade
-
Samsung Bioepis Co., Ltd.Completed
-
Merck Sharp & Dohme LLCCentocor, Inc.CompletedCrohn's Disease
-
Merck Sharp & Dohme LLCCentocor, Inc.Completed
-
BiocadCompletedAnkylosing SpondylitisRussian Federation, Belarus
-
Merck Sharp & Dohme LLCCompleted
-
Janssen Scientific Affairs, LLCTerminatedInflammatory Bowel DiseasesUnited States, Canada
-
Children's Hospital Medical Center, CincinnatiCrohn's and Colitis FoundationCompletedColitis, Ulcerative | Bowel Diseases, InflammatoryUnited States, Canada
-
University Hospitals Cleveland Medical CenterCentocor, Inc.CompletedCrohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease | Pyoderma GangrenosumUnited States
-
Massachusetts Eye and Ear InfirmaryWithdrawnStevens-Johnson Syndrome | Corneal BlindnessUnited States
-
Samsung Medical CenterCompletedCrohn's DiseaseKorea, Republic of